Gabon longs to cash in on sacred hallucinogenic remedy
Beneath yellow fruit, hidden within the roots of the iboga plant in the forests of Gabon, lies a sacred treasure that the country is keen to make the most of.
For centuries, religious devotees have eaten it -- a psychotropic shrub that users say has addiction-fighting powers.
It fascinates foreign visitors, psychiatric patients and rich pharmaceutical companies that want to market it.
Now this central African country, where its use is enshrined in ancestral tradition, is scrambling to avoid missing out on the boom.
Teddy Van Bonda Ndong, 31, an initiate in the Bwiti spiritual tradition, calls it "sacred wood". He consumes it in small amounts daily, he said, for his "mental and physical health".
"It has a lot of power to help human beings," added Stephen Windsor-Clive, a 68-year-old retiree.
"It's untapped. A mysterious force lies within this plant."
He travelled to Gabon from Britain and consumed iboga -- in a powder ground from its roots -- during a 10-day Bwiti ceremony.
He tried it with a view to adopting it as a treatment for his daughter, who suffers from mental illness.
- Economic potential -
Given the interest, Gabon is seeking to channel the plant onto the international marketplace.
Exports of iboga products, including its active ingredient ibogaine, are few and strictly regulated in the country.
It grows mostly in the wild, but "more and more effort is being made to domesticate the plant", said Florence Minko, an official in the forestry ministry.
Potentially toxic in high doses, ibogaine can have effects similar to LSD, mescaline or amphetamines, and cause anxiety and hallucinations.
But users believe it can help drug addicts kick their habit and treat post-traumatic stress and neurological illnesses.
Yoan Mboussou, a local microbiologist and Bwiti initiate, hopes to gain an export licence for the 500-milligram ibogaine capsules he produces at his laboratory near the capital Libreville.
He sells them in Gabon as a food supplement, declaring them to have "anti-fatigue, antioxidant and anti-addictive" qualities.
Iboga, he believes, "is a potential lever to develop the economy and the whole country".
- Tradition and IP -
Countries such as the United States and France class iboga as a narcotic because of health risks identified in studies, especially heart issues. But it is used in treatment centres in countries including the Netherlands, Mexico and Portugal.
Numerous studies have examined its effects -- both helpful and harmful -- and scientists have taken out dozens of international patents for ibogaine therapeutic treatments.
"Most of those are based on studies of iboga use by Gabonese people, particularly by Bwiti practitioners," said Yann Guignon, from the Gabonese conservation group Blessings Of The Forest.
Despite the plant's "colossal therapeutic benefits", "Gabon is clearly missing out on the economic potential of iboga," he added.
"It did not position itself in this market in time by developing productive iboga plantations, a national processing laboratory and a proper industrial policy."
Overseas laboratories meanwhile have worked out how to make synthetic ibogaine and to extract it from other plants, such as Voacanga africana.
That flowering tree is available in greater quantities in Ghana and Mexico, which "can produce ibogaine at unbeatable prices", said Guignon.
And "Gabonese traditional knowledge is not protected by intellectual property regulations."
Currently only one company in Gabon has a licence to export iboga products -- though Minko, from the forestry ministry, said the country hopes this number will rise in the coming years.
She said companies were likely to produce more, spurred by revenue guarantees under the Nagoya Protocol, an international agreement on biological diversity and resource-sharing.
She wants the country to obtain a "made in Gabon" certificate of origin for iboga.
"This is a huge resource for Gabon. We have drawn up a national strategy for the conservation and sustainable use of the product," she said.
"Gatherings will soon be organised, bringing together all the groups concerned: NGOs, traditional practitioners and scientists."
- Soothing properties -
After harvesting iboga to the sound of traditional harps and consuming it in the initiation ceremony, Stephen Windsor-Clive was convinced by the benefits of iboga.
"I definitely want to bring my daughter here and have her have the experience," he said.
"This is my last attempt to find something which might be of assistance to her."
Another visitor, Tafara Kennedy Chinyere, travelled from Zimbabwe to discover Gabon and found, in the initiation, relief from anxiety and his "inner demons".
"I feel good in my body, in myself," he said, sitting under a tree after the ceremony.
"I feel like the iboga helped me to let go of things that you no longer need in your life."
lnf/emp/rlp/kjm/phz
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News24
an hour ago
- News24
Gauteng's food safety campaign faces uphill battle in Naledi where 10 children died
Supplied/Gauteng department of health Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Start your FREE trial now


News24
6 hours ago
- News24
It's the ‘Donald disease' that's making us sick
Our so-called HIV 'key populations' — men who have sex with men, transgender women, sex workers and people who inject drugs, and, in Africa also young women — have been hard-hit ever since the Trump administration stopped most of its HIV funding in February. Key populations have a much higher chance of getting HIV than general populations, which is why Pepfar, over the past decade, allocated most of its funds to programmes working with such groups. With the 12 specialised key population clinics in South Africa funded by the US government and now shuttered, getting treatment at government clinics has been difficult, if not impossible, for some. 'Hello, sis. How are you? I hope you're fine. I mean, I'm not.' A lot has been going on out there, he told Bhekisisa in the voicemail, one of the many we recently received. 'You know, I'm a gay guy. I have sex with other men, without wearing condoms now, because when I try to fetch them from my local clinic, I'm told I get judged and told I want too many. You know what's happening in our industry.' We will call him Nkosi. Because he has sex with men and because his industry is sex work and because no one in the small community where he lives knows that he is gay or what he does for work. He even has a 'girlfriend' so people will think he's straight. Sex work has always been a dangerous profession. But ever since the Trump administration stopped most of its HIV funding in February, it's become even more risky. The World Health Organisation says gay and bisexual men like Nkosi's chance of contracting HIV through sex is 26 higher than that of the general population. Male sex workers are even more likely to get infected with the virus. That is what makes sex workers, as well as gay and bisexual men, what researchers call a ' key population ' in the HIV world. Other key populations are gay and bisexual men, transgender people, people who inject drugs, and, in Africa, also young women between the ages of 15 and 24. Because so many new HIV infections happen in these groups, the US government's Aids fund, Pepfar, has, for the past decades, invested most of its funds in programmes working with these groups. But the 12 specialised clinics for key populations, supported by the US government's Aids fund, Pepfar, have now been shut down. Gone, too, are their health workers specially trained in how to work without discrimination. Gone is their tailor-made HIV treatment and testing services; their specialised mental health support; and the condoms and lubricants they handed out for protection against HIV and other sexually transmitted infections. Gone are the two-monthly anti-HIV jabs and that some of these clinics handed out as part of studies — and the daily anti-HIV pills, which they distributed without any judgement. Although government clinics also stock the daily anti-HIV pill, which, if used correctly, can reduce someone's chance of getting HIV through sex to close to 0, people like Nkosi, research shows, are often treated badly by health workers at state clinics, making them wary to return. Preventive medicines like the daily pill are called pre-exposure prophylaxis, or PrEP, because they stop infection by preventing a germ such as HIV from penetrating someone's cells. 'So sometimes I don't have PrEP,' says Nkosi. 'A partner can tell me he is on PrEP, but I don't trust that. Because where is he getting PrEP? Where am I going to get it? The black market? 'I don't know if it is even the real thing. Is it a counterfeit? Lube? That's another thing — you use everything, anything, as long as it's got jelly in it. The last time I did that I had an itchy penis for a week.' Nkosi calls the domino effect of the Trump administration's decision to pull funding 'the Donald disease because it is being caused by this guy, one man.' 'It's like crossing the freeway every day the way we're living now. One day, I know I'm gonna die.' What's with key populations? When Health Minister Aaron Motsoaledi called a press conference in May to present his '18 facts' about the crisis, eight of those points were about what government is doing to make sure the patients from those specialised clinics — over 63 300 patients — were taken care of and that their files have been transferred to the nearest government facility. But why is there so much focus on these communities? UNAids says more than half of all new infections in 2022, around the world, came from key populations — and infections don't stay within those groups. 'Even the most self-interested people should be heavily invested in treatment and prevention of these populations,' says Francois Venter, who heads up the health research organisation, Ezintsha, at Wits University. 'There's no clean, magical division between key populations and general populations. It's a Venn diagram of married men sleeping with sex workers, of drug-using populations interacting with your ostensibly innocent kids, gay men with your straight presenting son, all needing HIV prevention and treatment programmes.' Although we have medicines like PrEP to prevent people from getting infected with HIV and antiretroviral drugs (ARVs) for HIV-infected people, which, if taken correctly, reduce their chance of transmitting the virus to others to 0, having the medications available, is just a small part of the solution. What's more difficult is to get medication to people and to convince people to use it, and to use it correctly. Studies, for example, show that getting people to use the anti-HIV pill, also called oral PrEP, each day, has been a struggle — and those who do use it, often don't use it each day, the less often it's used, the less well it works. Moreover, United Nations targets that South Africa needs to reach by the end of 2025, show that we struggle with convincing people who know they're infected with HIV, to take treatment — and stay on it. Researchers estimate that of South Africa's 8-million people with HIV, 1.1-million people who have been diagnosed with HIV, are not on treatment. Some of the 1.1-million choose not to start treatment, but an even larger proportion, who do go on treatment, cycle in and out of it. READ | 'It erases the very existence of people like me': Activists tackle doctors' anti-trans stance Pepfar programmes funded thousands of 'foot soldiers', such as community health workers, adherence counsellors, data collectors and youth workers, who went into communities with mobile clinics to find people who stopped their treatment, or to make ARVs easier to get by making it possible for people to collect their medicine from community halls, shops or private pharmacies close to where they live. That's why having lost at least half of those workers — we're likely to lose the other half at the end of the US financial year in September — is such a tragedy. And why, if we do nothing to replace them, modelling studies show, there's a high chance that we see up to almost 300 000 extra HIV infections over the next four years and a 38% increase in Aids deaths. The difficulty with state clinics and key populations Government clinics are mostly not geared towards key populations, because they serve everyone. And because many health workers' own prejudices so often interfere with the way in which they treat patients such as sex workers, gay and bisexual men, or teens who ask for condoms or PrEP, such groups frequently feel uncomfortable to use state health services. Stigma and discrimination in public clinics — doled out by security guards, cleaners, health workers and patients in waiting rooms — keep people away from HIV treatment and prevention. Researchers who surveyed over 9 000 people in key populations found that less than half, and in some cases not even a quarter, said they were treated well; about one in five said they were blocked from getting services. Motsoaledi says he's trying to fix that by now training 1 012 clinicians and 2 377 non-clinician workers at government facilities in non-discriminatory healthcare. But despite similar trainings having been conducted for years already, discrimination remains rife. Because funding cuts mean already understaffed government health clinics now have even fewer staff, many people with HIV, or those wanting PrEP, have to travel further for treatment, or wait in long queues. As politicians, activists and researchers duke it out from labs and clinics and press conferences, many of those most at risk, like Nkosi, have been left to fend for themselves. Here are some of their stories — we collected the stories via voice notes with the help of health workers who worked for Pepfar programmes that have now been defunded. Female sex worker: 'My child is going to be infected' 'Yoh, life is very hard. Since all this happened, life has been very, very hard.' 'I have tried to go to the public clinic for my medication. But as sex workers, we are not being helped. We are scared to go to the government clinic to treat sexually transmitted infections because we are seen as dirty people who go and sleep around. We even struggle to get condoms. We are now forced to do business without protection because it is only our source of income and it's the way that we put food on the table. My worry now is that I am pregnant and my child is going to be infected because I'm not taking my ARVs, and I have defaulted for two months now.' READ | Elon Musk's estranged trans daughter, Vivian, makes bold modelling debut Transgender woman: 'The future is dark' 'I'm a transgender woman. My pronouns are she.' 'When the clinic closed, I was about to run out of medication so I went to the government clinic in my area. I introduced myself to the receptionist and the lady asked me what kind of treatment I was taking. I told her ARVs and that I'm virally suppressed [when people use their treatment correctly the virus can't replicate, leaving so little virus in their bodies that they can't infect others], so I can't transmit HIV to others. 'The lady told me that they can't help me, and I need to bring the transfer letter. I told her that the clinic is closed so I don't have the transfer letter. I asked to speak to the manager and the manager also refused to help me. The manager! How can she let someone who is HIV-positive go home without medication? 'I had to call one of my friends and she gave me one container. If you're not taking your medication consistently, you're going to get sick, you're gonna die. And the future? The future is dark.' Migrant farm worker: 'Lose my job? Or risk my health?' 'When we were told that the clinic was closed, I was actually in another town trying to get a seasonal job on the farms. But when I went to the nearest clinic, I was told that I needed to get a transfer letter. So, I ended up sharing medication with friends. But then their medication also ran out. 'Then I got a job on the farm. Before the mobile clinics came to the farms and we had our clinical sessions there. The nurse was there, the social worker was there. Now we went to the clinic and spent the whole day there because we had to follow the queues. And because our jobs were not permanent jobs, you know, you just get a job if you apply by the gate. So, if you are not there by the gate on that day, then the boss will automatically think that you are no longer interested in the job, so they employ someone else. 'I went to the government clinic and asked to get at least three months' supply. But the clinic said no because it was my first initiation, so I had to come back. So, I went back to the farm to see if I could still have my job. I found that I was no longer employed because they had to take up someone else. 'What am I going to do? If I go to the clinic, I stand a chance of losing my job. If I stay at my job I am at risk of getting sick.'
Yahoo
11 hours ago
- Yahoo
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. To learn more about HTL Biotechnology: LinkedIn: HTL Biotechnology X: @HTL_Biotech Instagram: @htlbiotechnology Press contact Nathalie Chevallon - HTL Biotechnologynchevallon@ View original content: SOURCE HTL Biotechnology